OW 177
Alternative Names: OTG W9I; OW-177Latest Information Update: 28 Feb 2024
At a glance
- Originator Octagon Therapeutics
- Class Small molecules
- Mechanism of Action B cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 30 Jan 2020 OW 177 is available for licensing as of 30 Jan 2020. https://www.octagontherapeutics.com/
- 29 Jan 2020 Early research in Autoimmune disorders in USA (Octagon Therapeutics pipeline, January 2020)